[Correspondence] Sharing clinical trial data
The debate about sharing of clinical trial data is getting more intense. In January, 2016, The Lancet published, along with other journals of the International Committee of Medical Journal Editors, a proposal about sharing of clinical trial data.1 Initiatives like the AllTrials Campaign demand that all trial results are reported. However, sharing of patient data has an inherent risk of re-identification, and patient data can be de-identified in different ways with various pros and cons. Some pharmaceutical companies take legal action against data sharing (eg, because of data protection issues), which might result in long-lasting legal disputes.